STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Henrik Lundvall

Head of content

Henrik has extensive experience in senior roles within international media and tech companies, including TT, Expressen, Microsoft, Axel Springer and Lifesum. At Yazen, he is Head of Content, with responsibility for strategy, marketing and in-app content, working closely with product, medical and tech teams.

LinkedIn logo
Portrait imageOrange stylized human head with colorful flowers and vines growing out from the top and back.

Henrik Lundvall has a solid background in leadership roles across international digital media and tech companies. He started his career in local media in Sweden and has since held senior roles at TT, Expressen and Microsoft, where he worked as Operations Lead. Within the Axel Springer group, he was responsible for launching the company’s products across 28 international markets, and he has also been Managing Editor at Lifesum.

At Yazen, Henrik is Head of Content. He’s responsible for everything related to content across the business – from content and communications strategy to marketing, in-app content and business development. In his role, he leads cross-functional teams and works closely with product, doctors and tech teams to make sure the content is evidence-based, engaging and genuinely useful for the people using Yazen.

Articles by

Henrik Lundvall

Ozempic (semaglutide) in the treatment of obesity

Ozempic is a prescription medicine containing semaglutide as its active substance. This medicine was originally approved for the treatment of type 2 diabetes, but has since also been shown to contribute to clinically significant weight loss. Semaglutide has demonstrated significant improvements in body weight and metabolic markers in studies involving individuals with overweight or obesity. To make an informed decision about treatment, it is important that the person receives accurate information about how Ozempic works, who it is suitable for, and how it may affect long-term health (1,2).

Wegovy (semaglutide) in the treatment of obesity

Wegovy is a prescription medicine that can help people living with overweight or obesity lose weight in an effective and safe way. It is important to understand how Wegovy works, who may benefit from the treatment, and how the medicine affects weight loss and health. To make an informed decision about treatment with Wegovy, it is essential to have access to accurate and sufficient information.

Semaglutide for weight loss – information about the medicine

An increasing number of people today are living with overweight or obesity. Semaglutide has become one of the most effective medical treatments to help many people lose weight (1).

Semaglutide was originally developed as a treatment for type 2 diabetes, but clinical trials showed significant weight loss. The medication Wegovy (semaglutide 2.4 mg) is currently approved for weight management in adults with a BMI ≥ 30, or ≥ 27 with weight-related comorbidity (2).

Are weight loss and fat loss the same thing?

Many people who want to improve their health talk about “losing weight” – but what does that actually mean? Is the goal to weigh less, or to have less body fat? The difference is crucial for both health and results. To choose the right strategy, you need to understand the distinction between weight loss and fat loss. Even though they may sound like the same thing, they have different effects on our bodies and our health.